Hideki Garren - 15 Sep 2022 Form 4 Insider Report for PROTHENA CORP PUBLIC LTD CO (PRTA)

Role: Chief Medical Officer
Signature: /s/ Michael Malecek, as attorney-in-fact for Hideki Garren
Issuer symbol: PRTA
Transactions as of: 15 Sep 2022
Net transactions value: -$20,400
Form type: 4
Filing time: 16 Sep 2022, 21:32:09 UTC
Previous filing: 03 Aug 2022
Next filing: 05 Oct 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRTA	Ordinary Shares, par value $0.01 per share	Options Exercise	$99,600	+4,000		$24.90	4,000	15 Sep 2022	Direct
transaction	PRTA	Ordinary Shares, par value $0.01 per share	Sale	$120,000	-4,000	-100%	$30.00	0	15 Sep 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRTA	Stock Option (Right to Buy)	Options Exercise	$0	-4,000	-1.7%	$0.000000	234,000	15 Sep 2022	Ordinary Shares	4,000	$24.90	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2	The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 5, 2022 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Content

The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 5, 2022 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.